However, the differing effects of TRPC6 knockout in animal models of NTS, FSGS, and diabetic kidney disease suggest that targeting TRPC6 to treat glomerular disease processes is likely to be disease-specific. This evidence concerns the gene TRPC6 and focal segmental glomerulosclerosis.